GeoVax Labs (GOVX)

• Market cap: $8.74M
• 1 day: -8.08%
• 5 days: -17.05%
• 1 month: -44.70%
• 3 months: -62.64%
• 6 months: -58.73%
• Year to date: -66.55%
• 1 year: -43.18%
• 5 years: -98.12%
• 10 years: -98.12%
• Sector: Healthcare
• Industry: Biotechnology

About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Employees: 17

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

6% more funds holding

Funds holding: 17 [Q3] → 18 (+1) [Q4]

2.2% less ownership

Funds ownership: 5.26% [Q3] → 3.07% (-2.2%) [Q4]

34% less capital invested

Capital invested by funds: $1.08M [Q3] → $716K (-$367K) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 864% upside
• Avg. target: $11 1,226% upside
• High target: $14 1,588% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Vernon Bernardino 18% 1-year accuracy 13 / 71 met price target	864% upside $8	Buy Reiterated	16 Apr 2025
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target	1,588% upside $14	Buy Maintained	15 Apr 2025